Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | 1 | 7 | — | — | 8 |
Thromboembolism | D013923 | HP_0001907 | — | — | 1 | 7 | — | — | 8 |
Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | 2 | — | — | 2 |
Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thrombosis | D013927 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Semuloparin sodium |
INN | semuloparin sodium |
Description | Semuloparin (INN, USAN) is an experimental antithrombotic being developed by Sanofi-Aventis and belongs to the group of low molecular weight heparins (LMWH). It has completed Phase III clinical trials for the prevention of thromboembolism following various kinds of surgery such as hip replacement, as well as for patients undergoing chemotherapy.
|
Classification | Oligosaccharide |
Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108718 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | V5T10N50RD (ChemIDplus, GSRS) |